Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hind A. Alkhatabi"'
Autor:
Huma Rafiq, Junjian Hu, Mohammed Ageeli Hakami, Ali Hazazi, Mubarak A. Alamri, Hind A. Alkhatabi, Arif Mahmood, Bader S. Alotaibi, Abdul Wadood, Xiaoyun Huang
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract The signal transducer and activator of transcription 3 (STAT3) plays a fundamental role in the growth and regulation of cellular life. Activation and over-expression of STAT3 have been implicated in many cancers including solid blood tumors
Externí odkaz:
https://doaj.org/article/62990f78628f4c37ac1381e7adbcb989
Autor:
Hind A. Alkhatabi, Samir F. Zohny, Mohammed Razeeth Shait Mohammed, Hani Choudhry, Mohd Rehan, Aamir Ahmad, Farid Ahmed, Mohammad Imran Khan
Publikováno v:
Antioxidants, Vol 11, Iss 3, p 461 (2022)
Venetoclax (ABT199) is a selective B-cell lymphoma 2 (BCL-2) inhibitor. The US FDA recently approved it to be used in combination with low-dose cytarabine or hypomethylating agents in acute myeloid leukemia (AML) or elderly patients non-eligible for
Externí odkaz:
https://doaj.org/article/69e02b1fb97a4ee0b38ea800bb0836f9
Autor:
Mahmood Hassan Dalhat, Mohammed Razeeth Shait Mohammed, Hind Ali Alkhatabi, Mohd Rehan, Aamir Ahmad, Hani Choudhry, Mohammad Imran Khan
Publikováno v:
Clinical and Translational Medicine, Vol 12, Iss 9, Pp n/a-n/a (2022)
Abstract Background N‐4 cytidine acetylation (ac4C) is an epitranscriptomics modification catalyzed by N‐acetyltransferase 10 (NAT10); important for cellular mRNA stability, rRNA biogenesis, cell proliferation and epithelial to mesenchymal transi
Externí odkaz:
https://doaj.org/article/dc3edc36bba4405ea737e159585b34dc
Autor:
Amar Ajmal, Hind A Alkhatabi, Roaa M. Alreemi, Mubarak A. Alamri, Asaad Khalid, Ashraf N. Abdalla, Bader S. Alotaibi, Abdul Wadood
Publikováno v:
BMC Chemistry, Vol 18, Iss 1, Pp 1-14 (2024)
Abstract Lung cancer is a disease with a high mortality rate and it is the number one cause of cancer death globally. Approximately 12–14% of non-small cell lung cancers are caused by mutations in KRASG12C. The KRASG12C is one of the most prevalent
Externí odkaz:
https://doaj.org/article/cc592fd289c745519d9d8ac7abf9ade9